why choose us

First received: January 12, 2023

Clinical Trial: Combination Therapy in Cancers With Mutations in DNA Repair Genes

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Solid Tumor

Study Type: INTERVENTIONAL


Official Title: Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes

Brief Summary: The purpose of this phase 1 clinical trials is to determine whether niraparib (a Poly (ADP-ribose) polymerase inhibitor (PARPi)) can be safely combined with irinotecan with manageable toxicity and reasonable efficacy.Emerging evidence suggest that PARPi is an effective therapeutic strategy in a wider subset of solid tumors that may have defective homologous recombination (HR) or DNA repair gene mutations.BReast CAncer gene (BRCA), partner and localizer of BRCA2 (PALB2), and various other DNA repair germline…

Read more